On Tuesday, Qlik Technologies Inc (NASDAQ:QLIK)’s shares inclined 1.65%, and closed at $32.62, as Qlik Technologies (QLIK), declared that it is the top “cross-industry” vendor in the KLAS Report, “Healthcare Analytics: Moving Toward the Continuum of Care,” for having the best understanding of healthcare analytics and for being considered one of the most important vendors to a customer’s organization in terms of their future BI and analytics plans. Qlik also scored well above average in all other categories, counting data aggregation across multiple data sources, data aggregation across the continuum of care and most important to the organization.
The 2015 annual perception report by KLAS strives to address the challenges faced by healthcare organizations in their adoption of analytics and highlights the vendors perceived as being the most capable within these areas. Vendors are categorized as “cross-industry” providers, “large HIT” (electronic medical record or EMR) companies, and “healthcare niche” organizations. Qlik is considered a cross industry provider together with Oracle, IBM, SAP, Microsoft, and Tableau.
“As part of our strategy for the US healthcare sector, Qlik has focused on expanding key partnerships within healthcare niche organizations and EMR providers. Specifically, our partnership with Health Catalyst has assisted us expand into new organizations, while our partnership with Epic has opened doors for new use cases among existing clients,” said Chris Christy, National Healthcare Market Director, Qlik. “Our strong partnerships together with the value delivered via our solutions Qlik® Sense and QlikView® have assisted us connect with customers across the healthcare industry to turn their data into insights, improving decision making and ultimately transforming the way they deliver patient care.”
Qlik Technologies Inc. provides user-driven business intelligence solutions that enable customers to make business decisions. The corporation develops, commercializes, and implements software products and related services. It offers QlikView, which enables business users to explore data; ask and answer their own stream of questions; and follow their own path to insight on their own, or collaborate across teams and organizations.
Autodesk, Inc (NASDAQ:ADSK)’s shares raised 1.63%, and settled at $60.69, during the last trading session on Tuesday, formerly on March 23, Autodesk, Inc (ADSK), declared the availability of AutoCAD 2016, the latest release of one of the world’s leading computer-aided design (CAD) applications.
The 2016 release comprises scores of new features that accelerate the 2D and 3D design, documentation and joint venture process while enriching the on-screen experience of creating almost any shape imaginable. In addition, users can confidently share their work with others using TrustedDWG™ technology, the original and most accurate way to store and exchange design data.
“AutoCAD 2016 makes detailing and documentation work faster, while stunning visual enhancements bring a new level of clarity and depth to every aspect of a design,” said Amy Bunszel, vice president of AutoCAD products, Autodesk. “Our customers will also appreciate productivity boosts like improved PDF output and tighter coordination with Building Information Modeling (BIM).”
Autodesk, Inc. operates as a design software and services corporation worldwide. The corporation’s Architecture, Engineering and Construction segment offers Autodesk Building Design Suites to manage various phases of design and construction; Autodesk Revit products that provide model-based design and documentation systems; Autodesk Infrastructure Design Suites; AutoCAD Civil 3D products that offer a surveying, design, analysis, and documentation solution; and AutoCAD Map 3D software, which offers direct access to data needed for infrastructure planning, design, and administration.
At the end of Tuesday’s trade, Depomed Inc (NASDAQ:DEPO)’s shares picked up 1.58%, and closed at $23.16, soon after Depomed (DEPO), stated that it has closed the attainment of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise comprises: NUCYNTA® ER (tapentadol) extended release tablets indicated for the administration of pain, counting neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA® (tapentadol), an immediate release version of tapentadol, for administration of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched. NUCYNTA is now the flagship asset in Depomed’s growing portfolio of pain and neurology specialty pharmaceuticals.
Transition Highlights:
- Depomed will start shipping NUCYNTA the week of April 6, reflecting a price adjustment made after closing the deal
- Quintiles, the contract sales organization that promoted the NUCYNTA franchise for Janssen, will continue to support these products for Depomed from now until re-launch in June
- Depomed anticipates its expanded sales force supporting NUCYNTA, Gralise, Cambia and Zipsor to be fully deployed at re-launch
- Depomed will introduce new product positioning and marketing support focusing on the uniqueness of the molecule and its dual mechanism of action (MOA)
- The $575 million loan to complete financing of the transaction closed as predictable, with no dilution to shareholders
- The corporation plans to update 2015 guidance inclusive of NUCYNTA sales as part of the first quarter financial report in May
Depomed, Inc., a specialty pharmaceutical corporation, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the administration of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults.
MicroStrategy Incorporated (NASDAQ:MSTR), ended its Tuesday’s trading session with 0.15% gained, and closed at $170.28, after MicroStrategy Incorporated (MSTR), declared the availability of the on-premise version of MicroStrategy Usher™, a powerful platform designed to provide advanced security and analytics for business processes and systems across the enterprise.
The product replaces traditional passwords with biometric mobile identity and multi-factor authentication, and offers streamlined security administration capabilities. MicroStrategy Usher features comprises digital badges, geo-fenced and time-fenced access restrictions, and Touch ID access on mobile devices.
User-friendly and quick-to-deploy, MicroStrategy Usher enables an enterprise to:
- Secure physical entryways with digital keys that can access leading PACS systems, counting Lenel, Honeywell, Datawatch, Paxton, and S2 Security.
- Provide a single Usher badge to enable users to log into enterprise, cloud, and SAML 2.0-based applications. Supported applications comprise Salesforce.com, Google Apps, MicroStrategy, and Microsoft applications, among others.
- Validate user identities in-person or over the phone with numeric Usher codes, Bluetooth peer discovery, and fractal-based sight codes.
- Enable users to conveniently access workstations by low energy Bluetooth or by scanning a QR code, eliminating the need to enter a username and password.
- Gain a near real-time, 360-degree view into identity activities to detect anomalies and abnormal usage patterns in order to enhance enterprise risk administration, streamline business processes, and reduce fraud.
MicroStrategy Incorporated designs, develops, markets, and sells enterprise-ready analytics, mobile, and security software platforms worldwide. It offers MicroStrategy Analytics Platform that delivers reports and dashboards, and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web; and MicroStrategy Analytics Desktop to create data visualizations and dashboards.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
